CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy of HCC treatment with Proteasome Inhibitor Bortezomib is increased by Oncolytic Virotherapy mediated downregulation of Mcl-1 and Bip
DOI 10.1055/s-0029-1191861
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Boozari, T Wirth, N Woller, MP Manns, S Kubicka, F Kühnel
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Virotherapy using conditionally replicating adenoviral vectors provides a challenging tool for the tumor treatment. The proteasome inhibitor Bortezomib has been established as anti-cancer agent but potential interference with virotherapy if applied in combination is unkown. Therefore we investigated cytolytic efficacy of either single or combined treaments of hTERT-Ad virotherapy (MOI 25) and/or Bortezomib treatment…
Zitieren
Zitierempfehlung
B Boozari, T Wirth, N Woller, MP Manns, S Kubicka, F Kühnel (2009) Efficacy of HCC treatment with Proteasome Inhibitor Bortezomib is increased by Oncolytic Virotherapy mediated downregulation of Mcl-1 and Bip. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0029-1191861
Mit CareLit weiterarbeiten